Viewing Study NCT06041503

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:09 PM
Ignite Modification Date: 2026-06-04 @ 5:22 AM
Study NCT ID: NCT06041503
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2023-09-15
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Adenocarcinoma of the Bladder View
None Squamous Cell Carcinoma of the Bladder View
None Testicular Germ Cell Tumors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotherapy View
None nectin 4 View
None rare genitourinary cancers View
None programmed cell death 1 ligand 1 View